Rapamycin and Ageing: When, for How Long, and How Much?
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The drug rapamycin is the only pharmacological agent thus far shown to reproducibly extend lifespan and delay a subset of age-associated pathologies in multiple strains of mice. Unfortunately, the vast majority of aging-related studies on rapamycin in mice have been performed at a single dose of the drug delivered in encapsulated form through the diet. Recently, the National Institute on Aging Interventions Testing Program reported that a three-fold higher dose of dietary rapamycin results in a significantly greater increase in lifespan. This observation demonstrates that current studies of the effects of rapamycin on lifespan and healthspan in mice are being performed under conditions that are sub-optimal. Here I argue that the failure to properly determine the dose and timing response profile for rapamycin with respect to healthy aging represents a major barrier for the field. This barrier continues to hamper our ability to gain mechanistic insights and may threaten efforts to translate these findings into interventions that promote healthy aging in people.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 7×
“Current evidence suggests that initiating rapamycin delivery at 600 days of age in mice is nearly as effective as beginning treatment at 9 months, at least for the 14 ppm rapamycin diet (Harrison et al., 2009; Miller et al., 2011), and there is growing evidence that several measures of healthspan can be positively imp…”
BackgroundInfluentialmTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676 · cited 7×
“…mechanistic target of rapamycin (mTOR) is a nutrient and growth factor responsive kinase that modulates lifespan in species from yeast to mice (Johnson et al., 2013b). mTOR exists in two complexes within cells, mTOR complex I (mTORC1) and mTOR complex 2 (mTORC2) (Laplante and Sabatini, 2012).”
BackgroundInfluentialRegulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients
Kaeberlein, M., Powers, R. W., Steffen, K. K., Westman, E. A., Hu, D., Dang, N., Kerr, E. O., Kirkland, K. T., Fields, S., & Kennedy, B. K. (2005) · Science · doi:10.1126/science.1115535 · Cited by 1,293
Self-citationRapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120
Influence of TOR kinase on lifespan in C. elegans
Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A. L., Orosz, L., & Müller, F. (2003) · Nature · doi:10.1038/426620a · Cited by 1,057
Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila Melanogaster
Bjedov, I., Toivonen, J. M., Kerr, F., Slack, C., Jacobson, J., Foley, A., & Partridge, L. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.010 · Cited by 1,057
mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680
TOR Signaling and Rapamycin Influence Longevity by Regulating SKN-1/Nrf and DAF-16/FoxO
Robida-Stubbs, S., Glover-Cutter, K., Lamming, D. W., Mizunuma, M., Narasimhan, S. D., Neumann-Haefelin, E., Sabatini, D. M., & Blackwell, T. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.007 · Cited by 648
Rapamycin extends murine lifespan but has limited effects on aging
Neff, F., Flores-Dominguez, D., Ryan, D. P., Horsch, M., Schröder, S., Adler, T., Afonso, L. C., Aguilar-Pimentel, J. A., Becker, L., Garrett, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67674 · Cited by 374
Cited by
Urfer, S. R., Kaeberlein, T. L., Mailheau, S., Bergman, P. J., Creevy, K. E., Promislow, D. E. L., & Kaeberlein, M. (2017) · GeroScience · doi:10.1007/s11357-017-9972-z · Cited by 158
Self-citationFasting and rapamycin: diabetes versus benevolent glucose intolerance
Blagosklonny, M. V. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1822-8 · Cited by 74
The role of the TOR pathway in mediating the link between nutrition and longevity
Lushchak, O., Strilbytska, O., Piskovatska, V., Storey, K. B., Koliada, A., & Vaiserman, A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.03.005 · Cited by 73
Kreouzi, M., Theodorakis, N., & Constantinou, C. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276221118494 · Cited by 48
Senescence in aging and disorders of the central nervous system
Swenson, B. L., Meyer, C. F., Bussian, T. J., & Baker, D. J. (2019) · Translational Medicine of Aging · doi:10.1016/j.tma.2019.01.002 · Cited by 24
Metadata
- Authors
- Kaeberlein, M.
- Venue
- Journal of Genetics and Genomics
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 41
- Issue
- 9
- Pages
- 459-463
- ISSN
- 1873-5533 (ISSN-L)
- 1673-8527
- OpenAlex
- W2152296761
- Cited by
- 48
- References
- 10
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin and Ageing: When, for How Long, and How Much? https://app.cochat.ai/papers/10.1016/j.jgg.2014.06.009
- The paper
- Kaeberlein, M. (2014). Rapamycin and Ageing: When, for How Long, and How Much? Journal of Genetics and Genomics. https://doi.org/10.1016/j.jgg.2014.06.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.